Literature DB >> 22441938

PDE5 inhibitor promotes melanin synthesis through the PKG pathway in B16 melanoma cells.

Xiaodong Zhang1, Guirui Yan, Jun Ji, Jingwei Wu, Xiaoyun Sun, Jingshan Shen, Hualiang Jiang, Heyao Wang.   

Abstract

PDE inhibitors could increase cellular cGMP levels and are used to treat erectile dysfunction as well as pulmonary arterial hypertension. cGMP production was reported to be necessary for UVB-induced melanin synthesis, however, the effect of PDE5 inhibitor on melanin synthesis has not been examined. We found that PDE5 inhibitor (sildenafil or vardenafil) and the cGMP analog 8-CPT-cGMP stimulated CREB phosphorylation, leading to increased tyrosinase expression and melanin synthesis, which was counteracted by KT5823, a selective cGMP-dependent protein kinase (PKG) inhibitor. However, KT5823 did not affect cAMP-elevating agent-mediated melanin synthesis, indicating that KT5823 selectively inhibited cGMP-induced melanin synthesis. This is the first study to find that PDE5 inhibitor can promote melanin synthesis and reveal that PKG-dependent CREB phosphorylation and tyrosinase expression is involved in cGMP-induced melanin synthesis. Our results suggest that PDE5 inhibitor may be beneficial for the treatment of hypopigmentation diseases.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22441938     DOI: 10.1002/jcb.24147

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  13 in total

1.  PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells.

Authors:  Jane L Roberts; Laurence Booth; Adam Conley; Nichola Cruickshanks; Mark Malkin; Rakesh C Kukreja; Steven Grant; Andrew Poklepovic; Paul Dent
Journal:  Cancer Biol Ther       Date:  2014-03-20       Impact factor: 4.742

2.  Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells.

Authors:  Laurence Booth; Jane L Roberts; Nichola Cruickshanks; Adam Conley; David E Durrant; Anindita Das; Paul B Fisher; Rakesh C Kukreja; Steven Grant; Andrew Poklepovic; Paul Dent
Journal:  Mol Pharmacol       Date:  2013-12-18       Impact factor: 4.436

3.  Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study.

Authors:  Wen-Qing Li; Abrar A Qureshi; Kathleen C Robinson; Jiali Han
Journal:  JAMA Intern Med       Date:  2014-06       Impact factor: 21.873

4.  GRP78/BiP/HSPA5/Dna K is a universal therapeutic target for human disease.

Authors:  Laurence Booth; Jane L Roberts; Devin R Cash; Seyedmehrad Tavallai; Sophonie Jean; Abigail Fidanza; Tanya Cruz-Luna; Paul Siembiba; Kelly A Cycon; Cynthia N Cornelissen; Paul Dent
Journal:  J Cell Physiol       Date:  2015-07       Impact factor: 6.384

5.  Chronic inhibition of cyclic guanosine monophosphate-specific phosphodiesterase 5 prevented cardiac fibrosis through inhibition of transforming growth factor β-induced Smad signaling.

Authors:  Wei Gong; Mengwen Yan; Junxiong Chen; Sandip Chaugai; Chen Chen; Daowen Wang
Journal:  Front Med       Date:  2014-11-22       Impact factor: 4.592

6.  Regulation of OSU-03012 toxicity by ER stress proteins and ER stress-inducing drugs.

Authors:  Laurence Booth; Jane L Roberts; Nichola Cruickshanks; Steven Grant; Andrew Poklepovic; Paul Dent
Journal:  Mol Cancer Ther       Date:  2014-08-07       Impact factor: 6.261

7.  Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo.

Authors:  Xiao-Long Mei; Yang Yang; Yao-Jun Zhang; Yong Li; Jin-Ming Zhao; Jian-Ge Qiu; Wen-Ji Zhang; Qi-Wei Jiang; You-Qiu Xue; Di-Wei Zheng; Yao Chen; Wu-Ming Qin; Meng-Ning Wei; Zhi Shi
Journal:  Am J Cancer Res       Date:  2015-10-15       Impact factor: 6.166

8.  OSU-03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood-Brain Barrier: Implications for Anti-Cancer Therapies.

Authors:  Laurence Booth; Jane L Roberts; Mehrad Tavallai; Aida Nourbakhsh; John Chuckalovcak; Jori Carter; Andrew Poklepovic; Paul Dent
Journal:  J Cell Physiol       Date:  2015-08       Impact factor: 6.384

9.  GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases.

Authors:  Jane L Roberts; Mehrad Tavallai; Aida Nourbakhsh; Abigail Fidanza; Tanya Cruz-Luna; Elizabeth Smith; Paul Siembida; Pascale Plamondon; Kelly A Cycon; Christopher D Doern; Laurence Booth; Paul Dent
Journal:  J Cell Physiol       Date:  2015-10       Impact factor: 6.384

10.  Phosphodiesterase Type 5 Inhibitors and Risk of Malignant Melanoma: Matched Cohort Study Using Primary Care Data from the UK Clinical Practice Research Datalink.

Authors:  Anthony Matthews; Sinéad M Langan; Ian J Douglas; Liam Smeeth; Krishnan Bhaskaran
Journal:  PLoS Med       Date:  2016-06-14       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.